Arecor Therapeutics plc (LON:AREC) Insider Sarah Jennifer Howell Acquires 21,077 Shares

Arecor Therapeutics plc (LON:AREC) insider Sarah Jennifer Howell purchased 21,077 shares of the firm’s stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average price of GBX 47 ($0.64) per share, with a total value of £9,906.19 ($13,410.30).

Arecor Therapeutics Stock Up 3.5%

Shares of Arecor Therapeutics stock opened at GBX 42.94 ($0.58) on Friday. Arecor Therapeutics plc has a 52-week low of GBX 35.40 ($0.48) and a 52-week high of GBX 170 ($2.30). The company has a 50 day moving average of GBX 40.80 and a 200 day moving average of GBX 55.77. The company has a quick ratio of 6.24, a current ratio of 1.37 and a debt-to-equity ratio of 5.51. The company has a market capitalization of £16.21 million, a P/E ratio of -1.52 and a beta of -0.18.

Arecor Therapeutics (LON:AREC) last released its quarterly earnings data on Tuesday, April 22nd. The company reported GBX (0.31) ($0.00) earnings per share for the quarter. Arecor Therapeutics had a negative return on equity of 118.67% and a negative net margin of 176.89%. As a group, research analysts forecast that Arecor Therapeutics plc will post -0.35 EPS for the current fiscal year.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.